Research programme: cardiovascular disease - EPIRUS Biopharmaceuticals
Alternative Names: Cardiovascular disease research programme - EPIRUS BiopharmaceuticalsLatest Information Update: 01 Aug 2016
At a glance
- Originator Neuromed Pharmaceuticals
- Developer EPIRUS Biopharmaceuticals
- Class Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 17 Jul 2014 Discontinued - Preclinical for Cardiovascular disorders in Canada (unspecified route)
- 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals